BRPI0815493A2 - Composto, uso de um composto, composição faramcêutica, método para a terapia de dor, e, processo para preparar um composto. - Google Patents

Composto, uso de um composto, composição faramcêutica, método para a terapia de dor, e, processo para preparar um composto.

Info

Publication number: BRPI0815493A2
Authority: BR; Brazil
Prior art keywords: compound; preparing; pharmaceutical composition; therapy method; pain therapy
Prior art date: 2007-08-17

Application number

BRPI0815493-7A2A

Other languages

English (en)

Inventor

Sara Beha

William Brown

Shawnn Johnstone

Ziping Liu

Daniel Page

Miroslaw Tomaszewski

Zhong-Yong Wei

Shi Yi Yue

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-17

Filing date

2008-08-15

Publication date

2015-02-10

2008-08-15 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2015-02-10 Publication of BRPI0815493A2 publication Critical patent/BRPI0815493A2/pt

Links

150000001875 compounds Chemical class 0.000 title 3
238000004519 manufacturing process Methods 0.000 title 1
238000000034 method Methods 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Indole Compounds (AREA)

BRPI0815493-7A2A 2007-08-17 2008-08-15 Composto, uso de um composto, composição faramcêutica, método para a terapia de dor, e, processo para preparar um composto. BRPI0815493A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US95647807P	2007-08-17	2007-08-17
PCT/GB2008/050713 WO2009024819A1 (en)	2007-08-17	2008-08-15	Cannabinoid receptor ligands

Publications (1)

Publication Number	Publication Date
BRPI0815493A2 true BRPI0815493A2 (pt)	2015-02-10

Family

ID=39930420

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0815493-7A2A BRPI0815493A2 (pt)	2007-08-17	2008-08-15	Composto, uso de um composto, composição faramcêutica, método para a terapia de dor, e, processo para preparar um composto.

Country Status (16)

Country	Link
US (2)	US20090062251A1 (pt)
EP (1)	EP2190838A1 (pt)
JP (1)	JP2010536737A (pt)
KR (1)	KR20100061491A (pt)
CN (1)	CN101827838A (pt)
AR (1)	AR067954A1 (pt)
AU (1)	AU2008290325A1 (pt)
BR (1)	BRPI0815493A2 (pt)
CA (1)	CA2696697A1 (pt)
CL (1)	CL2008002431A1 (pt)
MX (1)	MX2010001574A (pt)
PE (1)	PE20090598A1 (pt)
RU (1)	RU2010102992A (pt)
TW (1)	TW200908963A (pt)
UY (1)	UY31294A1 (pt)
WO (1)	WO2009024819A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090062251A1 (en) *	2007-08-17	2009-03-05	Astrazeneca Ab	Novel Compounds 002
JP5756800B2 (ja) *	2009-06-16	2015-07-29	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体
ES2524304T3 (es) *	2009-12-11	2014-12-05	Bayer Intellectual Property Gmbh	Procedimiento para la preparación de 2,2-difluoroetilamina, así como de sus sales, partiendo de difluoroacetonitrilo
JP5841361B2 (ja) *	2011-06-29	2016-01-13	壽製薬株式会社	三環性化合物及びそれを含有する医薬組成物
JP6106452B2 (ja) *	2012-12-05	2017-03-29	公益財団法人微生物化学研究会	化合物、及びその製造方法、並びにリン酸オセルタミビルの製造方法
TWI648272B (zh)	2013-06-25	2019-01-21	美商必治妥美雅史谷比公司	經取代之四氫咔唑及咔唑甲醯胺化合物
WO2014210087A1 (en)	2013-06-25	2014-12-31	Bristol-Myers Squibb Company	Carbazole carboxamide compounds useful as kinase inhibitors
GB201312768D0 (en) *	2013-07-17	2013-08-28	Ge Healthcare Ltd	Work-up procedure
SI3209651T1 (sl)	2014-10-24	2019-12-31	Bristol-Myers Squibb Company	Derivati karbazola
EA034931B1 (ru)	2014-10-24	2020-04-08	Бристол-Майерс Сквибб Компани	Индолкарбоксамидные соединения
JP6592512B2 (ja)	2014-10-24	2019-10-16	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	三環式アトロプ異性体の化合物
WO2021173593A1 (en) *	2020-02-24	2021-09-02	Galyan Bio, Inc.	Indole compounds for the treatment of neurodegenerative diseases
EP4140481A1 (en) *	2021-08-26	2023-03-01	Galyan Bio, Inc.	Protein-oligomer binding agents and therapeutic uses thereof
WO2023025915A1 (en) *	2021-08-25	2023-03-02	Galyan Bio, Inc.	Protein-oligomer binding agents and therapeutic uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4009181A (en) *	1973-01-22	1977-02-22	Hoffmann-La Roche Inc.	Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US20050154202A1 (en) *	2002-04-05	2005-07-14	Hagmann William K.	Substituted aryl amides
TW200716628A (en) *	2005-03-22	2007-05-01	Astrazeneca Ab	Novel compounds
US20090062251A1 (en) *	2007-08-17	2009-03-05	Astrazeneca Ab	Novel Compounds 002

2008
- 2008-08-12 US US12/189,945 patent/US20090062251A1/en not_active Abandoned
- 2008-08-13 TW TW097130806A patent/TW200908963A/zh unknown
- 2008-08-15 EP EP08788684A patent/EP2190838A1/en not_active Withdrawn
- 2008-08-15 KR KR1020107005774A patent/KR20100061491A/ko not_active Withdrawn
- 2008-08-15 AR ARP080103573A patent/AR067954A1/es unknown
- 2008-08-15 UY UY31294A patent/UY31294A1/es unknown
- 2008-08-15 AU AU2008290325A patent/AU2008290325A1/en not_active Abandoned
- 2008-08-15 JP JP2010520636A patent/JP2010536737A/ja active Pending
- 2008-08-15 MX MX2010001574A patent/MX2010001574A/es not_active Application Discontinuation
- 2008-08-15 PE PE2008001393A patent/PE20090598A1/es not_active Application Discontinuation
- 2008-08-15 CA CA2696697A patent/CA2696697A1/en not_active Abandoned
- 2008-08-15 WO PCT/GB2008/050713 patent/WO2009024819A1/en not_active Ceased
- 2008-08-15 RU RU2010102992/04A patent/RU2010102992A/ru not_active Application Discontinuation
- 2008-08-15 CN CN200880112253A patent/CN101827838A/zh active Pending
- 2008-08-15 BR BRPI0815493-7A2A patent/BRPI0815493A2/pt not_active IP Right Cessation
- 2008-08-15 US US12/673,617 patent/US20110160180A1/en not_active Abandoned
- 2008-08-18 CL CL2008002431A patent/CL2008002431A1/es unknown

Also Published As

Publication number	Publication date
WO2009024819A1 (en)	2009-02-26
EP2190838A1 (en)	2010-06-02
MX2010001574A (es)	2010-03-15
AR067954A1 (es)	2009-10-28
AU2008290325A1 (en)	2009-02-26
CA2696697A1 (en)	2009-02-26
JP2010536737A (ja)	2010-12-02
CN101827838A (zh)	2010-09-08
PE20090598A1 (es)	2009-06-10
CL2008002431A1 (es)	2009-06-05
US20110160180A1 (en)	2011-06-30
RU2010102992A (ru)	2011-09-27
UY31294A1 (es)	2009-03-31
KR20100061491A (ko)	2010-06-07
TW200908963A (en)	2009-03-01
US20090062251A1 (en)	2009-03-05

Similar Documents

Publication	Publication Date	Title
BRPI0815493A2 (pt)	2015-02-10	Composto, uso de um composto, composição faramcêutica, método para a terapia de dor, e, processo para preparar um composto.
BRPI0914927A2 (pt)	2017-06-20	composto, composição farmacêutica, métodos para inibir a função de fak e de tratamento de um câncer, uso de um composto, e, processo para preparar um composto
BRPI1006162A2 (pt)	2019-09-24	"composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto".
BRPI0812851A2 (pt)	2014-09-30	Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
BRPI0811275A2 (pt)	2014-12-23	Composto, processo para a preparação do mesmo, composição farmacêutica, uso de composto, e, método para tratar doença
BRPI0922475A2 (pt)	2017-06-06	composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0813237A2 (pt)	2014-12-23	Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BRPI0810354A2 (pt)	2014-10-21	Composto, uso de um composto, composição farmacêutica, e, método de tratamento de um dispositivo de dor
BRPI0910734A2 (pt)	2015-09-29	composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo.
BRPI0818244A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0912348A2 (pt)	2015-10-13	composto de 3-aminocarbazol, composição farmacêutica, método para preparar um composto de 3-aminocarbazol, uso de um composto de 3-aminocarbazol, e, método para tratar ou prevenir doenças
BRPI0816331A2 (pt)	2015-04-14	Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto.
BRPI0816881A2 (pt)	2015-03-17	Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0818533A2 (pt)	2017-06-06	composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0906786A2 (pt)	2015-07-14	Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit.
BR122020011920A2 (pt)	2020-08-25	composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto
BRPI0907977A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0821299A2 (pt)	2015-06-16	Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
BRPI0917458A2 (pt)	2015-12-01	composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0913585A2 (pt)	2015-10-27	composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
BRPI1013396A2 (pt)	2016-03-29	composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto.
BRPI0907974A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0907992A2 (pt)	2017-06-13	composto ou sal farmaceuticamente aceitável do mesmo, uso do mesmo, composição farmacêutica, método de terapia em um animal de sangue quente, e, processo para preparar um composto
BRPI0914371A2 (pt)	2019-09-24	"composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo, e produto de combinação"
BRPI0822946A2 (pt)	2015-06-23	Derivado de carboxiamida, processo para preparação de derivado de carboxiamida, composição farmacêutica e uso do derivado de carboxiamida

Legal Events

Date	Code	Title	Description
2015-08-25	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.
2016-05-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.